Mode
Text Size
Log in / Sign up
N/A Completed N=356

Non-interventional Observational Study With Viramune (Nevirapine) and Various Drug Combinations in the Antiretroviral Combination Treatment of HIV-infected Patients Who Have Already Been Treated for Approx. 10 Years With Viramune

Source: ClinicalTrials.gov NCT00979420 ↗
Enrolled (actual)
356
Serious AEs
9.8%
Results posted
Aug 2012
Primary outcomePrimary: Change in log10 Viral Load From Baseline to Last Visit — -3.260; -0.099; -2.082 log10 copies/ml

Summary

The question that prompted this study is the extent to which results from clinical trials can be translated into everyday practice (external validity). An observation period of about 10 years extends far beyond the duration of clinical trials. First and foremost are questions about tolerability and the efficacy of an antiretroviral combination treatment with Viramune and other antiretroviral partners. In particular, adverse events will be recorded and the therapeutic effect will be monitored via the course of viral load and improvement of the immune system, based on the CD4 cell count.

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in log10 Viral Load From Baseline to Last Visit
-3.284; 0.000; -2.000 —
PRIMARY
Number of Participants With Viral Load <50 Copies/ml and >=50 Copies/ml at Last Visit
62; 33; 30; 1; 1; 3 —
PRIMARY
Change in Absolute CD4 Lymphocytes (CD4+) Cells From Baseline to Last Visit
380; 223.5; 228 —
PRIMARY
Change in Absolute CD4 Lymphocytes (CD4+ Cells) From Baseline to Last Visit
392; 283; 250 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Cholesterol During Study (Worst Grade) by Division of AIDS (DAIDS) Grade
11; 7; 4; 2; 26; 8 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Low-density Lipoprotein (LDL) Cholesterol During Study (Worst Grade) by DAIDS Grade
17; 9; 5; 9; 30; 6 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Triglycerides During Study (Worst Grade) by DAIDS Grade
72; 27; 17; 26; 0; 0 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Blood Glucose During Study (Worst Grade) by DAIDS Grade
50; 22; 21; 12; 83; 25 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Alanine Aminotransferase (ALT) During Study (Worst Grade) by DAIDS Grade
94; 32; 27; 28; 68; 17 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Aspartate Aminotransferase (AST) During Study (Worst Grade) by DAIDS Grade
105; 40; 40; 30; 58; 12 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Creatinine During Study (Worst Grade) by DAIDS Grade
152; 51; 50; 49; 13; 3 —
SECONDARY
Number of Patients With Laboratory Abnormalities for Hemoglobin During Study (Worst Grade) by DAIDS Grade
171; 53; 58; 54; 6; 1 —
SECONDARY
Duration of Intake of Viramune
131; 124; 131; 129 —
SECONDARY
History of Therapy With Antiretroviral Medication
178; 0; 0; 0; 0; 57 —
SECONDARY
Course of Absolute CD4+ Cell Count
734; 669; 491 —
SECONDARY
Number of Participants With Drug Related Adverse Events
0; 0; 1; 0 —

Eligibility Criteria

Inclusion criteria The inclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843) Exclusion criteria The exclusion criteria for treatment with Viramune plus other antiretroviral combination drugs are to be based on the current Information for Healthcare Professionals/SPC (R08-0843).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00979420). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search